文献速递血管炎

血清骨桥蛋白:巨细胞动脉炎疾病活动度的生物标志物及复发病程的预测因子,在托珠单抗治疗患者中潜在的临床实用性

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.
PubMed 文献 · RMD Open · 2017-12-22

在76例未治疗巨细胞动脉炎患者和25例年龄性别匹配对照中,血清骨桥蛋白在活动性疾病显著升高,且与复发相关;托珠单抗未改变培养动脉中骨桥蛋白表达,托珠单抗维持缓解者骨桥蛋白与糖皮质激素维持缓解者相似。

要点

  • 活动性巨细胞动脉炎患者血清骨桥蛋白显著高于对照。
  • 基线骨桥蛋白在复发者中显著高于非复发者。
  • 托珠单抗治疗下C反应蛋白不可测,但骨桥蛋白与糖皮质激素维持缓解者相似。

核心结论

  • 血清骨桥蛋白是巨细胞动脉炎疾病活动度的标志物和复发预测因子。
  • 由于骨桥蛋白并非完全依赖白介素6,血清骨桥蛋白可能是托珠单抗治疗患者合适的疾病活动度生物标志物。

研究设计与样本

  • 用免疫分析法检测76例未治疗巨细胞动脉炎患者和25例年龄性别匹配对照的血清骨桥蛋白。
  • 36例患者在糖皮质激素治疗1年后进行第二次检测,前瞻性记录基线临床和实验室发现以及随访期间复发和糖皮质激素需求。
  • 在32例接受糖皮质激素或托珠单抗治疗的缓解期患者中检测血清骨桥蛋白和C反应蛋白。
  • 在暴露和未暴露于托珠单抗的培养颞动脉中,用逆转录聚合酶链反应和免疫分析法检测骨桥蛋白mRNA表达和蛋白产生。

主要发现

  • 活动性疾病患者血清骨桥蛋白浓度(ng/mL;均值±标准差)为116.75±65.61,显著高于对照的41.10±22.65(p<0.001)。
  • 配对样本中患者进入疾病缓解时血清骨桥蛋白显著下降(活动性疾病102.45±57.72,缓解期46.47±23.49;p<0.001)。
  • 血清骨桥蛋白与血清白介素6相关(r=0.55;p<0.001)。
  • 基线血清骨桥蛋白浓度在复发者中显著高于非复发者(复发者129.08±74.24,非复发者90.63±41.02;p=0.03)。
  • 培养动脉中骨桥蛋白mRNA表达和蛋白产生未因托珠单抗而显著改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, tissue inflammation and remodelling. We explored the role of serum OPN (sOPN) as a biomarker in patients with giant cell arteritis (GCA). METHODS: sOPN was measured by immunoassay in 76 treatment-naïve patients with GCA and 25 age-matched and sex-matched controls. In 36 patients, a second measurement was performed after 1 year of glucocorticoid treatment. Baseline clinical and laboratory findings, as well as relapses and glucocorticoid requirements during follow-up, were prospectively recorded. sOPN and C reactive protein (CRP) were measured in 32 additional patients in remission treated with glucocorticoids or tocilizumab (interleukin 6 (IL-6) receptor antagonist). In cultured temporal arteries exposed and unexposed to tocilizumab, OPN mRNA expression and protein production were measured by reverse transcription polymerase chain reaction (RT-PCR) and immunoassay, respectively. RESULTS: sOPN concentration (ng/mL; mean±SD) was significantly elevated in patients with active disease (116.75±65.61) compared with controls (41.10±22.65; p<0.001). A significant decline in sOPN was observed in paired samples as patients entered disease remission (active disease 102.45±57.72, remission 46.47±23.49; p<0.001). sOPN correlated with serum IL-6 (r=0.55; p<0.001). Baseline sOPN concentrations were significantly higher in relapsing versus non-relapsing patients (relapsers 129.08±74.24, non-relapsers 90.63±41.02; p=0.03). OPN mRNA expression and protein production in cultured arteries were not significantly modified by tocilizumab. In tocilizumab-treated patients, CRP became undetectable, whereas sOPN was similar in patients in tocilizumab-maintained (51.91±36.25) or glucocorticoid-maintained remission (50.65±23.59; p=0.49). CONCLUSIONS: sOPN is a marker of disease activity and a predictor of relapse in GCA. Since OPN is not exclusively IL-6-dependent, sOPN might be a suitable disease activity biomarker in tocilizumab-treated patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Prieto-González S, Terrades-García N, Corbera-Bellalta M, et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open. 2017. PMID: 29299342. doi:10.1136/rmdopen-2017-000570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。